Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Goldinger SM, et al. Eur J Cancer. 2022 Feb;162:22-33. doi: 10.1016/j.ejca.2021.11.022. Epub 2021 Dec 21. Eur J Cancer. 2022. PMID: 34952480
[Current therapy of carcinoma of the skin].
Dummer R, Goldinger SM, Sailer E, French LE. Dummer R, et al. Among authors: goldinger sm. Ther Umsch. 2010 Sep;67(9):447-52. doi: 10.1024/0040-5930/a000078. Ther Umsch. 2010. PMID: 20806173 Review. German.
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schläppi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schönewolf N, Dummer R; Swiss Group for Clinical Cancer Research (SAKK). von Moos R, et al. Among authors: goldinger sm. Ann Oncol. 2012 Feb;23(2):531-6. doi: 10.1093/annonc/mdr126. Epub 2011 Apr 28. Ann Oncol. 2012. PMID: 21527587 Free article. Clinical Trial.
Cutaneous lymphomas: molecular pathways leading to new drugs.
Dummer R, Goldinger SM, Cozzio A, French LE, Karpova MB. Dummer R, et al. Among authors: goldinger sm. J Invest Dermatol. 2012 Mar;132(3 Pt 1):517-25. doi: 10.1038/jid.2011.370. Epub 2011 Dec 8. J Invest Dermatol. 2012. PMID: 22158559 Free article. Review.
Ultraviolet A and photosensitivity during vemurafenib therapy.
Dummer R, Rinderknecht J, Goldinger SM. Dummer R, et al. Among authors: goldinger sm. N Engl J Med. 2012 Feb 2;366(5):480-1. doi: 10.1056/NEJMc1113752. N Engl J Med. 2012. PMID: 22296092 Free article. No abstract available.
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, Egberts F, Hauschild A, Kashani-Sabet M, Goldinger SM, Dummer R, Long GV, McArthur G, Scherag A, Sucker A, Schadendorf D. Zimmer L, et al. Among authors: goldinger sm. J Clin Oncol. 2012 Jul 1;30(19):2375-83. doi: 10.1200/JCO.2011.41.1660. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614973 Free PMC article.
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, Willers J, Geldhof C, Prior JO, Kündig TM, Michielin O, Bachmann MF, Speiser DE. Goldinger SM, et al. Eur J Immunol. 2012 Nov;42(11):3049-61. doi: 10.1002/eji.201142361. Epub 2012 Aug 28. Eur J Immunol. 2012. PMID: 22806397 Free PMC article. Clinical Trial.
88 results